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Abstract
Objectives. Chlamydophila pneumoniae (C. pneumoniae) has been associated with atherosclerosis and abdominal aortic aneurysm
and is probably disseminated by peripheral blood mononuclear cells (PBMC). Viable and metabolically active bacteria can be
demonstrated by the presence of bacterial mRNA and on-going dissemination by the presence of bacteria in PBMC. The aim
of this study was to determine the prevalence of C. pneumoniae DNA and mRNA in aortic biopsies and C. pneumoniae DNA in
PBMC in thoracic aortic aneurysm and aortic dissection patients.
Design. Real-time PCR was used to detect C. pneumoniae DNA and mRNA in biopsies and C. pneumoniae DNA in PBMC.
Results. C. pneumoniae DNA was found in biopsies in 26% (6/23) of aneurysm patients and 11% (2/18) of dissection patients
but in none of the forensic autopsy controls. C. pneumoniae mRNA was not found in any biopsy, and all PBMC were
C. pneumoniae-negative.
Conclusions. Presence of C. pneumoniae DNA but not mRNA in aortic biopsies and no evidence of C. pneumoniae in PBMC
suggest that the infection in the aorta has passed into a state of persistence.
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Introduction
Thoracic aortic aneurysm and aortic dissection are
two major diseases affecting the thoracic aorta, both of
which may cause aortic rupture. In an aortic aneu-
rysm there is a dilatation of all three layers of the vessel
wall, compared to aortic dissection where there is a
splitting of the wall layers. The pathogenesis of most
cases of thoracic aortic aneurysm and dissection is
unknown, but in both diseases it is believed to
involve medial degeneration leading to a weakening
of the aortic wall (1). Known risk factors associated
with thoracic aortic aneurysms are bicuspid aortic
valve, Turner’s syndrome, and aortic arteritis
(e.g. Takayashu’s arteritis and giant cell arteritis)
(1). The most common associated risk factors for
the development of aortic dissection are hypertension
and advanced age; other risk factors are smoking,
dyslipidemia, diabetes mellitus, and Turner’s syn-
drome (2). Previously, a common cause of aneurysm
of the ascending aorta was syphilis, which today, with
declining incidence, is a rare cause.
In abdominal aortic aneurysm the main factor in
the pathogenesis is believed to be atherosclerosis, in
contrast to thoracic aortic aneurysm where athero-
sclerosis is found less often. The medial degenera-
tion of thoracic aortic aneurysms has previously been
described as a non-inﬂammatory disease; however,
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inﬂammatory cells in the aneurysm, indicating that
inﬂammation may have a role in the pathogenesis of
thoracic aortic aneurysms (3). Moreover, because
gene expression studies have demonstrated up-
regulated genes involved in inﬂammatory pro-
cesses, inﬂa m m a t i o nm a yh a v ear o l ea l s oi na o r t i c
dissection (4).
The respiratory pathogen Chlamydophila pneumo-
niae (C. pneumoniae) has been suggested to be
involved in the pathogenesis of atherosclerosis as
an initiator and stimulator of the chronic inﬂamma-
tion in the atherosclerotic plaque (5). This obligate
intracellular bacterium has a unique biphasic
life cycle that sometimes may be interrupted so
that the bacterium passes into a persistent state
unsusceptible to antibiotics (6). This ability of
C. pneumoniae to cause chronic disease makes it
difﬁcult to isolate from patient materials; in fact,
only a few studies have succeeded in culturing
C. pneumoniae from atherosclerotic tissue (7,8).
On the other hand, many studies have demonstrated
t h ep r e s e n c eo fC. pneumoniae DNA within the
atherosclerotic plaque (9); however, the presence
of bacterial DNA does not indicate whether the
bacterium is replicating and metabolically active or
not. Viable and metabolically active C. pneumoniae
may instead be proven by demonstration of bacterial
mRNA in the tissue, which has been done in biopsies
from the thoracic aorta in patients undergoing cor-
onary artery by-pass surgery (CABG) (10). Dissem-
ination of C. pneumoniae from the respiratory tract is
believed to be mediated by alveolar macrophages, and
in patients suffering from cardiovascular diseases
C. pneumoniae has often been detected in peripheral
bloodmononuclearcells(PBMC)ata higherdetection
rate than in healthy blood donors (11).
We have previously demonstrated the presence of
C. pneumoniae DNA in 12% of thoracic aortic aneu-
rysm biopsies and in none of six aortic dissection
biopsies (12). In a more recent study of patients
undergoing thoracic surgery because of thoracic aortic
aneurysm we have demonstrated the presence of
C. pneumoniae DNA in 26% of the thoracic aortic
aneurysms (13). Moreover, trace elements were mea-
sured in serum and aortic tissue in these patients, and
changes indicating on-going infection/inﬂammation
were demonstrated compared to healthy controls. In
the present study we aimed to further characterize the
state of the infection in these patients by investigating
the presence of C. pneumoniae mRNA in aortic tissue
as well as the presence of C. pneumoniae in PBMC.
Furthermore, the presence of C. pneumoniae was also
determined in patients undergoing thoracic surgery
because of Type A aortic dissection.
Material and methods
Patients and patient samples
In the present study 25 patients undergoing thoracic
surgery because of ascending thoracic aortic aneu-
rysm and 21 patients undergoing surgery because of
Type A aortic dissection were included. The aneu-
rysm patient group consisted of 17 men and 8 women
with a mean age of 61 years (range 30–81 years). The
aortic dissection patient group had a mean age of
61 years (range 45–78 years) and consisted of 15 men
and 6 women. Clinical data on patients are presented
in Table I. None of the patients had a hereditary
connective tissue disorder. Thoracic aortic wall biop-
sies were obtained from aneurysmatic or dissecting
tissue during surgery and aseptically divided. One
part of the biopsy was placed in RNAlater (Qiagen,
Solna, Sweden) overnight and then frozen at 70C,
and another was ﬁxed in 10% formalin solution. The
remaining parts of the biopsy were immediately frozen
at 70C until further processing. Blood samples
were collected for antibody and for preparation of
PBMC. Sera were frozen at 20C until further
Table I. Clinical data on thoracic aortic aneurysm (n = 25) and
aortic dissection patients (n = 21).
Aneurysm Dissection
Arterial
hypertension
44% (11/25) 71% (15/21)
Hyperlipidemia 28% (7/25) 14% (3/21)
Diabetes mellitus 4% (1/25)
a 0% (0/21)
Smoker/former
smoker
52% (13/25) 43% (9/21)
Angina pectoris 20% (5/25) 14% (3/21)
Previous myocardial
infarction
4% (1/25) 5% (1/21)
Undergoing CABG
in same operation
16% (4/25) 14% (3/21)
Undergoing aortic
valve replacement in
same operation
60% (15/25) 10% (2/21)
Normal coronary
arteries veriﬁed by
coronary
angiography
74% (17/23)
b nd
Bicuspid aortic valve 32% (8/25) nd
Family history of
cardiovascular
disease
20% (5/25) 5% (1/21)
aThe one patient with diabetes mellitus had Type 1 diabetes
mellitus.
bAngiography was not performed on two patients.
CABG = coronary artery by-pass surgery; nd = not determined.
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C. pneumoniae detection were collected using CTA
swabs transported in Tris-buffer (pH 7.0) and then
frozen at 70C until further analysis. For technical
reasons, biopsy specimens for DNA analyses were not
obtained from two aneurysm and three dissection
patients and not for mRNA analyses from one aneu-
rysm and two dissection patients.
Controls and control samples
Control specimens of thoracic aorta were collected
from 10 forensic autopsy controls consisting of
6 women and 4 men (mean age 61 years, range
41–80 years) without known cardiovascular disease.
Biopsies were aseptically divided and frozen at 70C
until analysis of C. pneumoniae DNA.
Preparation of PBMC
PBMC was isolated from 4 mL whole blood collected
in heparinized tubes. Blood samples were diluted with
an equal volume of phosphate buffered saline (PBS)
and layered onto Ficoll-Paque PLUS (Amersham
Biosciences, Uppsala, Sweden). Tubes were centri-
fuged for 30 minutes at 400 g, and the buffy-coat layer
was collected and washed with an equal volume of
PBS twice for 10 minutes at 100 g. Remaining cells
were suspended in approximately 0.5 mL of saline
solution and frozen at 70C.
DNA extraction
DNA was extracted from approximately 10 mg tissue,
throat and nasopharyngeal swabs, and 300 mL sus-
pended PBMC using the QiaAmp DNA mini kit
(Qiagen) according to instructions from the manu-
facturer and then eluted in 50 mL buffer AE. In every
round of extraction a negative no-template control
was processed in the same way as the samples.
RNA extraction
RNA was extracted from approximately 25 mg tissue
sampletreatedwithRNAlaterusingtheRNeasyﬁbrous
tissue mini kit (Qiagen) according to instructions from
the manufacturer and then eluted in 30 mL RNase-free
water. Aneurysm samples were homogenized in Lysing
MatrixAtubes(InVitroAB,Stockholm,Sweden)ona
Fast Prep FP120 (In Vitro AB, Stockholm, Sweden).
DissectionsampleswerehomogenizedinaTissueLyser
(Qiagen).RNAconcentrationinsampleswasmeasured
on a NanoDrop ND-1000 (NanoDrop Technologies
Inc., Wilmington, DE, USA) and subsequently stored
at 70C until further processing.
Reverse transcription PCR
cDNA was synthesized from RNA using the Super-
Script First-Strand Synthesis System for RT-PCR
(Invitrogen, Stockholm, Sweden) with random hex-
amers according to instructions from the manufac-
turer. In every RT-PCR reaction 14 mL of extracted
RNA was used.
Real-time PCR
DNA and cDNA samples were subjected to real-time
PCR,amplifyingafragmentoftheC.pneumoniaeompA
gene as has previously been described (10). Control
samples of a known concentration were included in
each run to verify PCR reproducibility by checking for
differences in Ct values. To verify that DNA extraction
had been accomplished, PCR against the human beta-
actin gene was run on all DNA samples (14). Further,
to verify that mRNA had not been degraded during
handling, all cDNA samples were tested for the pres-
ence of human glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) transcripts using TaqMan GAPDH
control reagents (Applied Biosystems, Stockholm,
Sweden) according to the manufacturer’si n s t r u c t i o n s .
In these reactions 5 mL of cDNA diluted 1:10 was
used. To check for possible PCR inhibition, several
negative DNA samples werespiked with C. pneumoniae
DNA, and real-time PCR was run.
Serology
Patient sera were tested for C. pneumoniae-speciﬁc
IgM, IgG, and IgA antibodies by the micro-immuno-
ﬂuorescence method using microscopic slides from
ANI Labsystems OY (Helsinki, Finland) (10).
Light microscopy
Biopsies were ﬁxed in 10% formalin solution. They
were embedded in parafﬁn, sectioned, and stained
with May Grünwald Giemsa (MGG), Alcian Blue,
van Gieson, Elastin (AVE), and Grocott stain.
Ethics
The Research Ethics Committee of the Faculty of
Medicine Uppsala University, Uppsala, approved this
study (D. No. 03 244). Informed consent was
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formed to the principles outlined in the Declaration of
Helsinki.
Results
Real-time PCR
Of the biopsy samples, 6/23 (26%) aneurysm and 2/18
(11%) dissection patient samples were positive for
C. pneumoniae DNA but none of the forensic control
specimens were. Concentrations of C. pneumoniae in
the positive samples were low, with only a few copies
of C. pneumoniae per mg tissue. In the PBMC all
patients tested negative for C. pneumoniae DNA.
Throat swabs were positive in 2/25 aneurysm patients
but in none of the 21 dissection patients. Nasopha-
ryngeal swabs were positive in 1/21 dissection patients
but in none of the 25 aneurysm patients. Those three
positive patients were only positive in the nasopharynx
or throat and not in the aorta. Moreover, all these
samples contained few copies of C. pneumoniae. All
aortic samples tested negative for C. pneumoniae
mRNA. Human GAPDH mRNA was found in all
cDNA, indicating that mRNA had not been
degraded. All DNA samples tested positive for the
presence of human beta-actin. Spiked samples
showed no signs of inhibition. The present results
of C. pneumoniae DNA in thoracic aortic aneurysm
biopsies and in forensic control specimens have pre-
viously been published (13).
Serology
IgG antibodies ‡1:64 against C. pneumoniae were
found in 56% (14/25) of the aneurysm patients, in
43% (9/21) of the dissection patients, in 83% (5/6) of
the aneurysm patients positive for C. pneumoniae in
the aorta, and in 50% (1/2) of the dissection patients
positive for C. pneumoniae in the aorta. Mean IgG titre
was 1:123 in the aneurysm patients and 1:67 in the
dissection patients. IgA antibodies ‡1:16 were found
in 28% (7/25) of the aneurysm patients with a mean
titre of 1:24. None of the dissection patients had any
IgA antibodies against C. pneumoniae.
Histopathology
Samples for histopathological analyses were obtained
from 23 thoracic aortic aneurysm patients and 17
aortic dissection patients. Among the eight patients
positive for C. pneumoniae in the aorta, samples
for histopathological analyses were obtained from
5/6 aneurysm patients and from both dissection
patients.Cysticmedianecrosis,atheroscleroticchanges,
and inﬂammatory cells in the biopsies are shown
in Table II.
Discussion
Chlamydophila pneumoniae (C. pneumoniae) DNA was
found in thoracic aortic biopsies from 26% (6/23) of
the patients undergoing surgery for thoracic aortic
aneurysm and from 11% (2/18) of the patients with
aortic dissection. C. pneumoniae-speciﬁc mRNA, a
marker of metabolically active bacteria, could not
be found in any of the biopsies, and none of the
patients had C. pneumoniae in their PBMC. This
may indicate that the acute phase of the
C. pneumoniae infection occurred long before the
patient was undergoing surgery and that the infection
in the aortic wall had passed into a state of persistence.
C. pneumoniae has been demonstrated by PCR in
abdominal aortic aneurysm in several studies (15,16),
and viable bacteria have been cultured from aneurys-
matic tissue (7). We have previously demonstrated
Table II. Histopathological analyses in aortic biopsies from thoracic aortic aneurysm and aortic dissection patients.
Thoracic aortic aneurysm patients (n = 23) Aortic dissection patients (n = 17)
C. pneumoniae-
positive (n = 5)
C. pneumoniae-
negative (n = 18)
C. pneumoniae-
positive (n = 2)
C. pneumoniae-
negative (n = 15)
Cystic medial necrosis 1/5 1/18 0/2 4/15
Atherosclerotic changes 1/5 8/18 1/2 1/15
Inﬂammatory cells 5/5 8/18
a 0/2 8/15
Atherosclerotic changes
and inﬂammatory cells
1/5 4/18 0/2 0/15
Cystic medial necrosis
and inﬂammatory cells
1/5 0/18 0/2 1/15
aP < 0.05, difference between Chlamydophila pneumoniae-positive and C. pneumoniae-negative aneurysm.
184 M. Edvinsson et al.C. pneumoniae DNA in 12% of thoracic aortic aneu-
rysm and in 0% of aortic dissection tissue (12),
whereas another group of investigators failed to dem-
onstrate the presence of C. pneumoniae in this kind of
tissue, as well as in abdominal aortic aneurysm (17).
Furthermore, another study failed to demonstrate the
presence of C. pneumoniae in Type A aortic dissection
tissue (18). In the present study C. pneumoniae DNA
was found in 26% of the thoracic aortic aneurysm
patients (13) and in 11% of the aortic dissection
patients but in none of the control aortic biopsies.
The higher prevalence in this new study than in our
previous one (12) may be due partly to the use of a
more sensitive PCR method and partly to a potential
patchy distribution of the bacteria (5).
In contrast to abdominal aortic aneurysm, athero-
sclerosis is believed to be an infrequent cause of
thoracic aortic aneurysm and of aortic dissection
(19). The aneurysm patients in this study had a rather
low degree of coronary artery stenosis, as veriﬁed by
coronary angiography. On the other hand, atheroscle-
rotic changes in the aneurysm were demonstrated by
histology in 9/23 patients; however, these changes
were not more prevalent in C. pneumoniae-positive
patients than in C. pneumoniae-negative patients.
Regarding presence of inﬂammatory cells, no differ-
ence was noted between aneurysm and dissection
biopsies. However, among the aneurysm biopsies,
inﬂammatory cells were signiﬁcantly more frequent
in C. pneumoniae-positive aneurysms than in
C. pneumoniae-negative aneurysms. No such differ-
ence existed among the dissection biopsies.
Presence of C. pneumoniae in circulating PBMC
may be associated with cardiovascular disease (11).
However, detection rates in different studies on such
patients vary between 0% (20) and 59%, and detec-
tion rates in healthy blood donors vary from 0% to
46% (11). Such wide variation can probably be
explained by differences in sampling, nucleic acid
extraction methods, and PCR techniques. To our
knowledge, this is the ﬁrst study of C. pneumoniae
in PBMC of thoracic aortic aneurysm. One study
has investigated the presence of C. pneumoniae in
PBMC in aortic dissection patients, and all patients
with Type A aortic dissection were negative for
C. pneumoniae DNA (18). All patients in this study
tested negative for C. pneumoniae in PBMC, indicat-
ing that the bacteria probably had disseminated to the
aorta long before the patient was in need of surgery.
Isolation of C. pneumoniae from atherosclerotic
tissue has only been successful in a few studies
(7,16), and then only after several passages. This
work is time-consuming, with a high risk of contam-
ination. Instead, viable and metabolically active
C. pneumoniae can be demonstrated by the presence
of bacterial mRNA. We have previously shown that
patients undergoing CABG have C. pneumoniae
mRNA coding for the major outer membrane protein
in macroscopically normal thoracic aorta (10). How-
ever, in that study samples that were positive for
C. pneumoniae DNA were not always positive for
C. pneumoniae mRNA. Most of the aortic samples
in the present study were altered by advanced disease,
including ﬁbrosis and calciﬁcation, and they were all
negative for C. pneumoniae mRNA. All samples con-
tained rather low amounts of RNA but were, however,
positive for human cDNA, indicating that the mRNA
extraction had worked. This suggests that the bacteria
have entered into a persistent and non-active state in
the disease-altered tissue and are thus not producing
measurable amounts of mRNA.
C. pneumoniae antibodies were determined with the
micro-immunoﬂuorescence method. Considering the
age of the patients, antibody titres seemed to be in the
normal range (6), with 56% of the aneurysm patients
and 43% of the dissection patients having IgG against
C. pneumoniae.
Inﬂammatory cells have previously been demon-
strated in thoracic aortic aneurysms (21), and it has
been suggested that different antigens may be
involved in the formation of the aneurysms (3). These
antigens could possibly be micro-organisms, as we
have demonstrated the presence of C. pneumoniae in
the aneurysms and others have demonstrated other
bacteria in the aneurysms (22). Moreover, in vitro
studies have demonstrated that C. pneumoniae is able
to degrade elastin, a load-bearing protein in the aortic
wall (23), and these mechanisms may contribute to
the pathogenesis of the rupture of the aortic wall.
Certain changes in trace element concentrations
can be used as markers of infection/inﬂammation
(24). We have previously demonstrated such markers
in sera of patients undergoing surgery because of
aortic valve stenosis, where a large number of the
patients were positive for C. pneumoniae in the valve
(25). In a more recent study of sera and aortic biopsies
of the thoracic aortic aneurysm patients in the present
study we demonstrated trace element changes, indi-
cating on-going infection/inﬂammation in the patients
compared to healthy controls (13).
In conclusion, the results in the present study
demonstrate that C. pneumoniae may be found in
the aortic wall in thoracic aortic aneurysm patients
and aortic dissection patients though not in a meta-
bolically active state. Dissemination of C. pneumoniae
from the respiratory tract to the aortic wall may have
occurred long before the patient was in need of
thoracic surgery as no C. pneumoniae could be found
in the PBMC. This indicates that the C. pneumoniae
infection in the patients is not in an active state but has
C. pneumoniae in aortic aneurysm and dissection 185probably passed into a chronic state of persistence.
Further studies are needed to establish the role of
inﬂammation, which is possibly caused in some
patients by slow-growing bacteria, including
C. pneumoniae, in the pathogenesis of thoracic aortic
aneurysm and aortic dissection.
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